Cellular Stress Response (Hormesis) in Response to Bioactive Nutraceuticals with Relevance to Alzheimer Disease
Antioxidants & Redox Signaling · 2023-03 · 38 (7-9) · 643-669
DOI: 10.1089/ars.2022.0214 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antioxidants & Redox Signaling, online erschienen am 16.03.2023. Verfasst von D Allan Butterfield und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Kentucky, Lexington, Kentucky, USA. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 303 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Significance: Alzheimer's disease (AD) is the most common form of dementia associated with aging. As the large Baby Boomer population ages, risk of developing AD increases significantly, and this portion of the population will increase significantly over the next several decades. Recent Advances: Research suggests that a delay in the age of onset by 5 years can dramatically decrease both the incidence and cost of AD. In this review, the role of nuclear factor erythroid 2-related factor 2 (Nrf2) in AD is examined in the context of heme oxygenase-1 (HO-1) and biliverdin reductase-A (BVR-A) and the beneficial potential of selected bioactive nutraceuticals. Critical Issues: Nrf2, a transcription factor that binds to enhancer sequences in antioxidant response elements (ARE) of DNA, is significantly decreased in AD brain. Downstream targets of Nrf2 include, among other proteins, HO-1. BVR-A is activated when biliverdin is produced. Both HO-1 and BVR-A also are oxidatively or nitrosatively modified in AD brain and in its earlier stage, amnestic mild cognitive impairment (MCI), contributing to the oxidative stress, altered insulin signaling, and cellular damage observed in the pathogenesis and progression of AD. Bioactive nutraceuticals exhibit anti-inflammatory, antioxidant, and neuroprotective properties and are potential topics of future clinical research. Specifically, ferulic acid ethyl ester, sulforaphane, epigallocatechin-3-gallate, and resveratrol target Nrf2 and have shown potential to delay the progression of AD in animal models and in some studies involving MCI patients. Future Directions: Understanding the regulation of Nrf2 and its downstream targets can potentially elucidate therapeutic options for delaying the progression of AD. Antioxid. Redox Signal. 38, 643–669.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, University of Kentucky, Lexington, Kentucky, USA.
- Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA.
- Department of Biochemistry, Chemistry, and Physics, University of Mount Union, Alliance, Ohio, USA.
- Department of Chemistry, Eastern Kentucky University, Richmond, Kentucky, USA.
ORCID-Profile: D Allan Butterfield
Förderung
- NIA NIH HHS
Zitieren
APA
Butterfield, D. A., Boyd-Kimball, D., & Reed, T. T. (2023). Cellular Stress Response (Hormesis) in Response to Bioactive Nutraceuticals with Relevance to Alzheimer Disease. Antioxidants & Redox Signaling, 38(7-9), 643-669. https://doi.org/10.1089/ars.2022.0214
Vancouver
Butterfield DA, Boyd-Kimball D, Reed TT. Cellular Stress Response (Hormesis) in Response to Bioactive Nutraceuticals with Relevance to Alzheimer Disease. Antioxidants & Redox Signaling. 2023;38(7-9):643-669. doi:10.1089/ars.2022.0214
BibTeX
@article{Butterfield2023,
author = {Butterfield, D Allan and Boyd-Kimball, Debra and Reed, Tanea T},
title = {Cellular Stress Response (Hormesis) in Response to Bioactive Nutraceuticals with Relevance to Alzheimer Disease},
journal = {Antioxidants & Redox Signaling},
year = {2023},
volume = {38},
number = {7-9},
pages = {643--669},
doi = {10.1089/ars.2022.0214}
}
EUVIMED